- Home
- POR vs PTGX Comparison
POR vs PTGX Comparison
Compare POR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POR
- PTGX
- Stock Information
- Founded
- POR 1889
- PTGX 2006
- Country
- POR United States
- PTGX United States
- Employees
- POR N/A
- PTGX N/A
- Industry
- POR Electric Utilities: Central
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- POR Utilities
- PTGX Health Care
- Exchange
- POR Nasdaq
- PTGX Nasdaq
- Market Cap
- POR 4.7B
- PTGX 4.0B
- IPO Year
- POR N/A
- PTGX 2016
- Fundamental
- Price
- POR $44.61
- PTGX $77.57
- Analyst Decision
- POR Hold
- PTGX Strong Buy
- Analyst Count
- POR 11
- PTGX 8
- Target Price
- POR $46.30
- PTGX $74.13
- AVG Volume (30 Days)
- POR 1.1M
- PTGX 1.6M
- Earning Date
- POR 10-31-2025
- PTGX 11-06-2025
- Dividend Yield
- POR 4.71%
- PTGX N/A
- EPS Growth
- POR N/A
- PTGX N/A
- EPS
- POR 2.72
- PTGX 0.80
- Revenue
- POR $3,488,000,000.00
- PTGX $209,180,000.00
- Revenue This Year
- POR $4.88
- PTGX N/A
- Revenue Next Year
- POR $4.79
- PTGX $243.08
- P/E Ratio
- POR $16.38
- PTGX $96.33
- Revenue Growth
- POR 8.53
- PTGX N/A
- 52 Week Low
- POR $39.55
- PTGX $33.31
- 52 Week High
- POR $49.85
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- POR 63.29
- PTGX 63.15
- Support Level
- POR $43.15
- PTGX $74.62
- Resistance Level
- POR $44.21
- PTGX $93.25
- Average True Range (ATR)
- POR 0.58
- PTGX 4.76
- MACD
- POR 0.04
- PTGX 0.80
- Stochastic Oscillator
- POR 94.20
- PTGX 49.44
About POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation along with 100 megawatts of energy storage.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.